A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
In plain words A study of magnolia bark in people 18 and older, run by Sirt3 LLC. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Psoriasis.
- Male of female, aged 18 years or older at time of consent.
- Diagnosis of stable psoriasis affecting for at least 6 months confirmed by a dermatologist.
- Patients with psoriasis-associated comorbidities including psoriatic arthritis are permitted, as long as those comorbidities are not severe enough to require treatment with systemic therapies as defined in the exclusion criteria.
- Able to read and understand English.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Oral supplement containing 200mg Magnolia officinalis bark extract; Placebo
Registered summary
The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug). Participants will: * Take Viv or a placebo every day for 3 months. * Complete electronic questionnaires about their quality of life and psoriasis symptoms at the beginning of the study and again at 1 months and 3 months. The full summary is on the listing.
Where, as registered
1 US site in 1 state.